Cite
HARVARD Citation
El-Madani, M. et al. (2017). EVESOR, a model-based, multiparameter, Phase I trial to optimize the benefit/toxicity ratio of everolimus and sorafenib. Future oncology. pp. 679-693. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
El-Madani, M. et al. (2017). EVESOR, a model-based, multiparameter, Phase I trial to optimize the benefit/toxicity ratio of everolimus and sorafenib. Future oncology. pp. 679-693. [Online].